Elevated homocysteine levels in Parkinson's disease: Is there anything besides L-dopa treatment?

Current Medicinal Chemistry

Volumn 17, Issue 3, 2010, Pages 213-221

  Zoccolella, S ^a   Dell'Aquila, C ^b   Specchio, L M ^a   Logroscino, G ^b   Lamberti, P ^b  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE; LEVODOPA; VITAMIN B GROUP;

ALLELE; CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIETARY INTAKE; DOPAMINERGIC NERVE CELL; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; INCIDENCE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PUBLICATION; REVIEW; RISK FACTOR;

ANIMALS; ANTIPARKINSON AGENTS; HUMANS; HYPERHOMOCYSTEINEMIA; LEVODOPA; PARKINSON DISEASE;

EID: 77349104558     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710790149774     Document Type: Review

References (52)

1. Mattson, M.P.; Shea, T.B. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci., 2003, 26, 137-146.
2. Stanger, O.; Herrmann, W.; Pietrzik, K.; Fowler, B.; Geisel, J.; Dierkes, J.; Weger, M.; DACH-LIGA Homocystein, e.V. DACHLIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin. Chem. Lab. Med., 2003, 41, 1392-1403.
3. Selley, M.L.; Close, D.R.; Stern, S.E. The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol. Aging, 2002, 23, 383-388.
4. Finkelstein,J.D. The metabolism of homocysteine:pathways and regulaion. Eur. J. Pediatr., 1998,157, S40-S44.
5. Robert, K.; Pagès, C.; Ledru, A.; Delabar, J.; Caboche, J.; Janel, N. Regulation of extracellular signal-regulated kinase by homocysteine in hippocampus. Neuroscience, 2005, 133, 925-935.
6. Tjattas, L.; Ortiz, D.O.; Dhivant, S.; Mitton, K.; Rogers, E.; Shea, T.B. Folate deficiency and homocysteine induce toxicity in cultured dorsal root ganglion neurons via cytosolic calcium accumulation. Aging Cell, 2004, 3, 71-76.
7. Jara-Prado, A.; Ortega-Vazquez, A.; Martinez-Ruano, L., Rios, C.; Santamaria, A. Homocysteine-induced brain lipid peroxidation: effects of NMDA receptor blockade, antioxidant treatment, and nitric oxide synthase inhibition. Neurotox. Res., 2003, 5, 237-243.
8. Kruman, I.I.; Culmsee, C.; Chan, S.L.; Kruman, Y.; Guo, Z., Penix, L.; Mattson, M.P. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J. Neurosci., 2000, 20, 6920-6926.
9. Marsden, C.D. Basal ganglia disease. Lancet., 1982, 2, 1141-1147.
10. Morris, M.S. Homocysteine and Alzheimer's disease. Lancet. Neurol., 2003, 2, 425-428.
11. Quadri, P.; Fragiacomo, C.; Pezzati, R.; Zanda, E.; Forloni, G.; Tettamanti, M.; Lucca,U. Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am. J. Clin. Nutr., 2004, 80, 114-122.
12. Zoccolella, S.; Simone I.L.; Lamberti, P.; Samarelli, V.; Tortelli, R.; Serlenga, L.; Logroscino, G. Elevated plasma homocysteine levels in patients with amyotrophic lateral sclerosis. Neurology, 2008, 70, 222-225.
13. Miller, J.W.; Shukitt-Hale, B.; Villalobos-Molina, R.; Nadeau, M.R., Selhub, J.; Joseph, J.A. Effect of L-Dopa and the catechol-Omethyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin. Neuropharmacol., 1997, 20, 55-66.
14. Daly, D.; Miller, J.W.; Nadeau, M.R.; Selhub, J. The effect of ldopa administration and folate deficiency on plasma homocysteine concentrations in rats. J. Nutr. Biochem., 1997, 8, 634-640.
15. Zoccolella, S.; Martino, D.; Defazio, G.; Lamberti, P.; Livrea, P. Hyperhomocysteinemia in movement disorders: Current evidence and hypotheses. Curr. Vasc. Pharmacol., 2006, 4, 237-243.
16. Müller, T. Role of homocysteine in the treatment of Parkinson's disease. Expert. Rev. Neurother., 2008, 8, 957-967.
17. Postuma, R.B.; Lang, A. Homocysteine and levodopa. Should parkinson disease patients receive preventative therapy? Neurology., 2004, 63, 886-891.
18. Irizarry, M.C.; Gurol, M.E.; Raju, S.; Diaz-Arrastia, R.; Locascio, J.J.; Tennis, M.; Hyman, B.T.;Growdon, J.H.; Greenberg, S.M.; Bottiglieri, T. Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. Neurology, 2005, 65, 1402-1408.
19. Zoccolella, S.; dell'Aquila, C.; Abruzzese. G.; Antonini, A.; Bonuccelli, U.; Canesi, M.; Cristina, S.; Marchese, R.; Pacchetti, C.; Zagaglia, R.; Logroscino, G.; Defazio, G.; Lamberti, P.; Livrea, P. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia. Mov. Disord., 2009, 24, 1028-1033.
20. Camicioli, R.M.; Bouchard, T.P.; Somerville, M.J. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients. Mov. Disord., 2009, 24, 176-182.
21. de Lau, L.M.; Koudstaal, P.J.; van Meurs, J.B.; Uitterlinden, A.G.;, Hofman, A.; Breteler, M.M. Methylenetetrahydrofolate reductase C677T genotype and PD. Ann. Neurol., 2005, 57, 927-930.
22. Todorović, Z.; Dzoljić, E.; Novaković, I.; Mirković, D.; Stojanović, R.; Nesić, Z.; Krajinović, M.;, Prostran, M.; Kostić V. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. J. Neurol. Sci., 2006, 248, 56-61.
23. Lin, J.J.; Yueh, K.C.; Liu, C.S.; Liu, J.T.; Lin, S.Z. 5,10-methylenetetrahydrofolate reductase C677T gene polymorphism can influence age at onset of Parkinson's disease. Acta Neurol. Taiwan, 2007, 16, 150-157.
24. Religa, D.; Czyzewski, K.; Styczynska, M.; Peplonska, B.; Lokk, J.; Chodakowska-Zebrowska, M.;, Stepien, K.; Winblad, B.; Barcikowska, M. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease. Neurosci. Lett., 2006, 404, 56-60.
25. Harmon, D.L.; Ramsbottom, D.; Whitehead, A.S.; Ben-Shlomo, Y.; Davey-Smith, G. The thermolabile variant of 5,10-methylenetetrahydrofolate reductase is not associated with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry., 1997, 62, 671.
26. Wüllner, U.; Kölsch, H.; Linnebank, M. Methylenetetrahydrofolate reductase in Parkinson's disease. Ann. Neurol., 2005, 58, 972-973.
27. Dorszewska, J.; Florczak, J.; Rozycka, A.; Kempisty, B.; Jaroszewska-Kolecka, J.; Chojnacka, K.; Trzeciak, W.H.; Kozubski, W. Oxidative DNA damage and level of thiols as related to polymorphisms of MTHFR, MTR, MTHFD1 in Alzheimer's and Parkinson's diseases. Acta Neurobiol Exp (Wars) 2007;67:113-129.
28. Lutz, U.C.; Batra, A.; Wiatr, G.; Machicao, F.; Kolb, W.; Maurer, S.; Buchkremer, G.; Köhnke, M,D. levels among alcoholdependent patients. Significant impact of MTHFR C677T polymorphism on plasma homovanillic acid (HVA). Addict. Biol., 2007, 12, 100-105.
29. Momose,Y.; Murata, M.; Kobayashi, K.; Tachiwara, M.; Nakabayashi, Y.; Kanazawa, I.; Toda, T. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphism. Ann. Neurol., 2002, 51, 133-136.
30. Caccamo, D.; Gorgone, G.; Currò, M.; Paris, G.; Di Iorio, W.; Menichetti, C.; Belcastro, V.; Parnetti, L.; Rossi, A.; Pisani, F.; Ientile, R.; Calabresi, P. Effect of MTHFR polymorphisms on hyperhomocysteinemia in Levodopa treated parkinsonian patients. Neuromol. Med., 2007, 9, 249-254.
31. Yasui, K.; Kowa, H.; Nakaso, K.; Takeshima, T.; Nakashima, K. Plasma homocysteine and MTHFR C677T genotype in levodopatreated patients with PD. Neurology, 2000, 55, 437-440.
32. Rey-Yue, Y.; Sheu, J.J.; Yu, J.M.; Hu, C.J.; Tseng, I.J.; Ho, C.S.; Yeh, C.Y.; Hung, Y.L.; Chiang, T.R. Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopatreated and non-treated Parkinson's disease patients. J. Neurol. Sci., 2009; doi:10.1016/j.jns.2009.09.007.
33. Chen, H.; Zhang, S.M.; Schwarzschild, M.A.; Hernán, M.A.; Logroscino, G.; Willett, W.C.; Ascherio, A. Folate intake and risk of Parkinson's disease. Am. J. Epidemiol., 2004, 160, 368-375.
34. de Lau, L.M.; Koudstaal, P.J.; Witteman, J.C.; Hofman, A.; Breteler, M.M. Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology., 2006, 67, 315-318.
35. Gao, X.; Chen, H.; Fung, T.T.; Logroscino, G.; Schwarzschild, M.A.; Hu, F.B.; Ascherio, A. Prospective study of dietary pattern and risk of Parkinson disease. Am. J. Clin. Nutr., 2007, 86, 1486-1494.
36. dos Santos, E.F.; Brandt Busanello, E.N.; Miglioranza, A.; Zanatta, A.; Barchak, A.G.; Vargas, C.R.; Saute, J.; Rosa, C.; Carrion, M.J.; Camargo, D.; Dalbem, A.; da Costa, J.C.; de Sousa, M.S.R.; de Mello, R.C.R.; Wajner, M.. Evidence that folic acid deficiency is a major determinant of hypehomocysteinemia in Parkinson's disease. Metab. Brain Dis., 2009, 24, 257-269.
37. Ozkan, S.; Colak, O.; Kutlu, C.; Ertan, M.; Alatas, O. Plasma homocysteine levels in pergolide-treated Parkinson disease patients. Clin. Neuropharmacol., 2004, 27, 163-165.
38. Müller, T.; Werne, B.; Fowler, B.; Kuhn, W. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet, 1999, 354, 126-127.
39. Zoccolella, S.; Lamberti, P.; Armenise, E.; de Mari, M.; Lamberti, S.V.; Mastronardi, R.; Fraddosio, A.; Iliceto, G.; Livrea, P. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. Parkinsonism Relat. Disord., 2005, 11, 131-133.
40. Isobe, C.; Murata, T.; Sato, C.; Terayama, Y. Increase of total homocysteine ccentration in cerebrospinal fluid in patients with Alzheimer's Disease and Parkinson's Disease. Life Sci., 2005, 77, 1836-1843.
41. Heider, I.; Lehmensiek, V.; Lenk, T.; Müller, T.; Storch, A. Dopaminergic neurotoxicity of homocysteine and its derivatives in primary mesencephalic cultures. J. Neural. Transm. Suppl., 2004, 68, 1-13.
42. Zhao, W.Q.; Williams, Z.; Shepherd, K.R.; Reuben, J.S.; Lee, E.S.; Darling-Reed, S.; Lamango, N.; Soliman, K.F.; Charlton, C.G. Sadenosyl-methionine-induced apoptosis in PC12 cells. J. Neurosci. Res., 2002, 69, 519-529.
43. Agnati, L.F.; Ferré, S.; Genedani, S.; Leo, G.; Guidolin, D.; Filaferro, M.; Carriba, P.; Casadó, V.; Lluis, C.; Franco, R.; Woods, A.S.; Fuxe, K. Allosteric modulation of dopamine D2 receptors by homocysteine. J. Proteome Res., 2006, 5, 3077-3083.
44. Imamura, K.; Takeshima, T.; Nakaso, K.; Nakashima, K. Homocysteine is toxic for dopaminergic neurons in primary mesencephalic culture. Neuroreport, 2007, 18, 1319-1322.
45. Charlton, C.G.; Crowell, B.Jr. Striatal dopamine depletion, tremors, and hypokinesia following the intracranial injection of Sadenosylmethionine: a possible role of hypermethylation in parkinsonism. Mol. Chem. Neuropathol., 1995, 26, 269-284.
46. Duan, W.; Ladenheim, B.; Cutler, R.G.; Kruman, I.I.; Cadet, J.L.; Mattson, M.P. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J. Neurochem., 2002, 80, 101-110.
47. Shepherd, K.R.; Lee, E.S.; Schmued, L.; Jiao, Y.; Ali, S.F.; Oriaku, E.T.; Lamango, N.S.; Soliman, K.F.; Charlton, C.G. The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice. Pharmacol. Biochem. Behav., 2006, 83, 349-59.
48. Chandra, G.; Gangopadhyay, P.K.; Senthil Kumar, K.S.; Mohanakumar, K.P. Acute intranigral homocysteine administration produces stereotypic behavioral changes and striatal dopamine depletion in Sprague-Dawley rats. Brain. Res., 2006, 1075, 81-92.
49. Lee, E.S.Y.; Chen, H.; Soliman, K.F.A.; Charlton, C.G. Effects of homocysteine on the dopaminergic system and behavior in rodents. Neurotoxicology, 2005, 26, 361-371.
50. Gospe, S.M.; Gietzen, D.W.; Summers, P.J.; Lunetta, J.M.; Miller, J.W.; Selhub, J.; Ellis, W.G.; Clifford, A.J.l. Behavioral and neurochemical changes in folate-deficient mice. Physiol. Behav., 1995, 58, 935-941.
51. Fung, T.T.; Rimm, E.B.; Spiegelman, D.; Rifai, N.; Tofler, G.H.; Willett, W.C.; Hu, F.B. Association between dietary patterns and plasma biomarkers of obesity and cardiovascular disease risk. Am. J. Clin. Nutr., 2001, 73, 61-67.
52. Greve, A.; Butcher, S.P.; Griffiths, R. Synaptosomal plasma membrane transport of exicitatory sulphur amino acid transmitter candidates: kinetic characterisation and analysis of carrier specificity. J. Neurosci. Res., 1992, 32, 60-68.